Back

Pathophysiological and therapeutic implications of urocortin-2 in heart failure with preserved ejection fraction

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in basic science (2) Heart Failure HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Rui Adao

Complutense University of Madrid, Madrid (Spain)

5 More presentations in this session

Presentation thumbnail
Effects of recombinant GDF15 pretreatment on mitochondrial damage and cytotoxicity induced by doxorubicin in human stem cell-derived cardiomyocytes
Associate Professor E. Fung (Hong Kong, CN)
Abstract Slides Video
Presentation thumbnail
Evaluating the potential for SPAR to detect changes in ECGs with time matched disease progression in ATTR-Cardiac Myopathy a proof of concept study
Mr J. Rickard (London, GB)
Abstract Slides Video
Presentation thumbnail
Exploring nucleotide metabolism and nicotinamide riboside effects in hypertrophic cardiomyopathy
Ms K. Stawarska (Gdansk, PL)
Abstract Slides Video
Presentation thumbnail
Influence of subclinical hypothyroidism on systolic and diastolic cardiac function post-acute myocardial infarction: a prospective cohort study
Doctor N. Kurup (Gateshead, GB)
Abstract Slides Video
Presentation thumbnail
Connexin-43 deficiency in subsarcolemmal mitochondria of cardiomyocytes of dogs with chronic heart failure
Professor H. Sabbah (Detroit, US)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in basic science (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Urocortin-2 as a novel biomarker of clinical deterioration in HFpEF: a prospective cohort study
thumbnail
Congress Presentation
COR-1167, a new long-acting CRF2 receptor agonist, decreases congestion by improving cardiorenal function in a sheep model of worsening heart failure (WHF)
thumbnail
Congress Presentation
Effects of sacubitril-valsartan alone or in combination with dapagliflozin on aging-related heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources